BidaskClub downgraded shares of Ocular Therapeutix (NASDAQ:OCUL) from a hold rating to a sell rating in a report released on Tuesday.

Several other equities research analysts have also recently issued reports on the company. Cantor Fitzgerald set a $22.00 target price on Ocular Therapeutix and gave the stock a buy rating in a research note on Wednesday, October 3rd. ValuEngine raised Ocular Therapeutix from a sell rating to a hold rating in a research note on Thursday, September 20th. Piper Jaffray Companies assumed coverage on Ocular Therapeutix in a research note on Thursday, September 6th. They set an overweight rating for the company. JMP Securities set a $9.00 target price on Ocular Therapeutix and gave the stock a buy rating in a research note on Monday, August 20th. Finally, Zacks Investment Research cut Ocular Therapeutix from a buy rating to a hold rating in a research note on Wednesday, August 15th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $12.00.

Shares of Ocular Therapeutix stock opened at $6.08 on Tuesday. Ocular Therapeutix has a one year low of $3.30 and a one year high of $8.28. The company has a market cap of $265.51 million, a P/E ratio of -2.76 and a beta of 1.21. The company has a current ratio of 4.92, a quick ratio of 4.91 and a debt-to-equity ratio of 0.21.

Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.37). The firm had revenue of $0.65 million for the quarter, compared to the consensus estimate of $0.35 million. Ocular Therapeutix had a negative return on equity of 143.32% and a negative net margin of 2,814.72%. On average, research analysts predict that Ocular Therapeutix will post -1.53 earnings per share for the current year.

In other news, CEO Antony C. Mattessich acquired 20,000 shares of the company’s stock in a transaction dated Monday, August 20th. The stock was acquired at an average cost of $5.95 per share, with a total value of $119,000.00. Following the completion of the purchase, the chief executive officer now owns 57,900 shares of the company’s stock, valued at approximately $344,505. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Antony C. Mattessich acquired 16,900 shares of the company’s stock in a transaction dated Friday, August 10th. The stock was purchased at an average cost of $6.23 per share, with a total value of $105,287.00. Following the completion of the purchase, the insider now directly owns 37,900 shares of the company’s stock, valued at approximately $236,117. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 49,400 shares of company stock valued at $302,912. 15.90% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Jennison Associates LLC grew its stake in shares of Ocular Therapeutix by 1.2% in the second quarter. Jennison Associates LLC now owns 2,319,255 shares of the biopharmaceutical company’s stock valued at $15,655,000 after buying an additional 26,503 shares in the last quarter. BlackRock Inc. grew its stake in shares of Ocular Therapeutix by 15.9% in the second quarter. BlackRock Inc. now owns 1,965,882 shares of the biopharmaceutical company’s stock valued at $13,270,000 after buying an additional 269,270 shares in the last quarter. Opaleye Management Inc. acquired a new stake in shares of Ocular Therapeutix in the second quarter valued at $7,499,000. Northern Trust Corp grew its stake in shares of Ocular Therapeutix by 11.7% in the second quarter. Northern Trust Corp now owns 362,627 shares of the biopharmaceutical company’s stock valued at $2,447,000 after buying an additional 38,101 shares in the last quarter. Finally, Nottingham Advisors Inc. grew its stake in shares of Ocular Therapeutix by 30.5% in the second quarter. Nottingham Advisors Inc. now owns 191,766 shares of the biopharmaceutical company’s stock valued at $1,294,000 after buying an additional 44,820 shares in the last quarter. 56.65% of the stock is owned by institutional investors and hedge funds.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension.

Featured Story: Outstanding Shares and The Effect on Share Price

Analyst Recommendations for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.